ANVSAnnovis Bio, Inc.

NYSE annovisbio.com


$ 8.06 $ -1.20 (-12.93 %)    

Wednesday, 03-Jul-2024 12:59:41 EDT
QQQ $ 490.95 $ 4.06 (0.83 %)
DIA $ 392.84 $ -0.46 (-0.12 %)
SPY $ 551.46 $ 2.45 (0.45 %)
TLT $ 91.86 $ 1.19 (1.31 %)
GLD $ 217.99 $ 2.43 (1.13 %)
$ 8.08
$ 9.11
$ 0.00 x 0
$ 0.00 x 0
$ 7.38 - $ 9.21
$ 4.53 - $ 22.49
5,394,569
na
87.46M
$ 1.62
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-10-2024 03-31-2024 10-Q
2 03-29-2024 12-31-2023 10-K
3 11-08-2023 09-30-2023 10-Q
4 08-14-2023 06-30-2023 10-Q
5 05-10-2023 03-31-2023 10-Q
6 03-31-2023 12-31-2022 10-K
7 11-08-2022 09-30-2022 10-Q
8 08-08-2022 06-30-2022 10-Q
9 05-04-2022 03-31-2022 10-Q
10 03-02-2022 12-31-2021 10-K
11 11-03-2021 09-30-2021 10-Q
12 07-28-2021 06-30-2021 10-Q
13 05-06-2021 03-31-2021 10-Q
14 03-03-2021 12-31-2020 10-K
15 11-04-2020 09-30-2020 10-Q
16 07-29-2020 06-30-2020 10-Q
17 05-05-2020 03-31-2020 10-Q
18 03-25-2020 12-31-2019 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 whats-going-on-with-annovis-shares-today

Annovis Bio shares rise in premarket trading on positive Phase III Parkinson's study results for buntanetap, showing cognit...

 tesla-paramount-global-annovis-bio-eli-lilly-amazon-why-these-5-stocks-are-on-investors-radars-today

On Tuesday, the Dow Jones Industrial Average rose by 0.4%, closing at $39,331.85, while the S&P 500 also ended the day in p...

 rodman--renshaw-reiterates-buy-on-annovis-bio-maintains-67-price-target

Rodman & Renshaw analyst Elemer Piros reiterates Annovis Bio (NYSE:ANVS) with a Buy and maintains $67 price target.

 whats-going-with-annovis-bio-shares-tuesday

Annovis announced new data from its Phase III Parkinson's study. The study showed improvements on the Unified Parkinson'...

 annovis-bio-files-provisional-patent-for-new-manufacturing-process-of-crystalline-form-of-buntanetap-which-has-demonstrated-exceptional-stability-and-efficacy

This patent encompasses the methods for manufacturing the new crystalline form of buntanetap (CAS# 3032752-92-1), which has dem...

 hc-wainwright--co-reiterates-buy-on-annovis-bio-maintains-23-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Annovis Bio (NYSE:ANVS) with a Buy and maintains $23 price tar...

 annovis-bios-recent-phase-iiiii-alzheimers-study-of-buntanetap-showed-statistically-significant-efficacy-and-safety-in-both-carriers-and-non-carriers-of-apolipoprotein-e4-a-genetic-cause-of-ad

Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage drug platform company developing novel ...

 rodman--renshaw-initiates-coverage-on-annovis-bio-with-buy-rating-announces-price-target-of-67

Rodman & Renshaw initiates coverage on Annovis Bio (NYSE:ANVS) with a Buy rating and announces Price Target of $67.

 hc-wainwright--co-maintains-buy-on-annovis-bio-lowers-price-target-to-23

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Annovis Bio (NYSE:ANVS) with a Buy and lowers the price target ...